Cytune Pharma SAS
PPF Group owns a French biotechnology company Cytune Pharma SAS focused on researching and developing new therapies for immune modulation aimed at enhancing immune response of patients suffering from cancer and infectious diseases.
Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Autolus Therapeutics
Autolus Therapeutics plc (“Autolus”) is a leader in bio T cell programming technologies and is developing a pipeline of next generation T cell therapies targeting both hematological cancers and solid tumors. Focused on the development of precisely targeted, controlled and highly active CAR-T cell products, Autolus aims to provide T cell therapies with very favorable safety profile and enhanced clinical efficacy to better recognize cancer cells, break down their defense mechanisms, and attack and kill these cells.
Cellestia Biotech
Cellestia Biotech was founded in 2014 as a spin-off of the Swiss Federal Institute of Technology Lausanne (EPLF). Cellestia’s lead development compound is CB-103, a novel, first-in-class oral pan-NOTCH inhibitor with an innovative mode of action indicated for the treatment of patients with NOTCH-driven lymphomas and solid tumours.